TriSalus touts data for pressure-enabled drug-delivery tech

This article was originally published here

TriSalus Life Sciences logoTriSalus Life Sciences touted results today from a Phase Ib trial of its pressure-enabled drug-delivery tech for immunotherapy.

The company reported that delivering a concentrated dose of CAR-T cells at the site of a solid tumor using its technology was safe and contributed to positive clinical results.

Get the full story at our sister site, Drug Delivery Business News.

The post TriSalus touts data for pressure-enabled drug-delivery tech appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply